🚑 🚑 🚑
#POLICYBZR
While the fundamentals of the company looked rosy, the technicals on this chart are screaming for a "health check."
We are seeing a classic rejection at the ₹1,750–₹1,800 overhead resistance zone, and the "Policy" of buying every dip might finally be expiring.
Why the Premium might be "Capping" here:
The "Double Top" Trouble: Price has hit a wall at the previous peak. In technical terms, that’s a "Double Top"—in retail terms, that’s investors saying, "I'll take my profits and run, thanks!"
"Sell the News" Risk: With the Q3 results now fully priced in, the market is looking for the next catalyst. If the "AI-driven cost savings" don't show up immediately in the next monthly data, the "Growth-at-any-price" crowd might head for the exit.
The Valuation Gap: At these levels, PB Fintech is trading at a massive premium to global peers. Even with 165% PAT growth, the market eventually asks: "How much more can we front-run the future?"
#POLICYBZR
While the fundamentals of the company looked rosy, the technicals on this chart are screaming for a "health check."
We are seeing a classic rejection at the ₹1,750–₹1,800 overhead resistance zone, and the "Policy" of buying every dip might finally be expiring.
Why the Premium might be "Capping" here:
The "Double Top" Trouble: Price has hit a wall at the previous peak. In technical terms, that’s a "Double Top"—in retail terms, that’s investors saying, "I'll take my profits and run, thanks!"
"Sell the News" Risk: With the Q3 results now fully priced in, the market is looking for the next catalyst. If the "AI-driven cost savings" don't show up immediately in the next monthly data, the "Growth-at-any-price" crowd might head for the exit.
The Valuation Gap: At these levels, PB Fintech is trading at a massive premium to global peers. Even with 165% PAT growth, the market eventually asks: "How much more can we front-run the future?"
Trade closed: stop reached
Risk on!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.